Psoriatic Nail Dystrophy Associated With Erosive Damage at Distal Interphalangeal Joints
The presence of psoriatic nail dystrophy was linked to erosive damage at the distal interphalangeal joints.
All articles by Rheumatology Advisor Contributing Writer
Methotrexate Persistence, Adverse Drug Reactions in Juvenile Idiopathic Arthritis
Data show that more than half of patients with juvenile idiopathic arthritis were no longer on methotrexate therapy.
Belimumab Demonstrates Long-Term Safety, Efficacy in Systemic Lupus Erythematosus
Belimumab was well tolerated with no new safety concerns, and efficacy was maintained through 13 years of treatment.
Biomechanical CT More Cost-Effective Than DXA for Osteoporosis Screening
A biomechanical computed tomography program used to screen for osteoporosis appears to be a cost-effective alternative to standard care for adults age ≥65 years.
ANA Indicative of Poor Response to bDMARDs in RA
Development of antinuclear antibodies (ANA) could indicate poor response in patients with rheumatoid arthritis (RA) undergoing treatment with biological disease-modifying antirheumatic drugs (bDMARDs), according to a study published in Seminars in Arthritis and Rheumatism. In this prospective single-center cohort study, patients with RA were recruited to determine associations between treatment response and ANA development, during…
![Cardiovascular changes associated with AS may begin early in the disease process. Thus, assessment of cardiovascular risk should be routine for all patients affected with this disease. Preventing CVD or cardiovascular death depends on early identification and effective management of traditional cardiovascular risk factors such as hypertension or hypercholesterolemia. Despite their importance, screening and treatment of CVD risk factors in patients with rheumatic diseases are often suboptimal. One reason for suboptimal management may be confusion over who is responsible for monitoring cardiovascular risk in patients with AS.[14] The lack of disease-specific guidelines for risk assessment is another concern. Ensuring patients with AS are screened and managed appropriately for CVD will require collaboration between the rheumatologist or specialist nurse, the general practitioner, and the patient.[14]](https://1fxghyessyy2gaob23ygwzph-wpengine.netdna-ssl.com/wp-content/uploads/sites/18/2019/01/8heartmonitorvitalsignsts_1032652-544x306.jpg)
Cardiovascular Risk Higher Among Black Patients With Rheumatoid Arthritis
Researchers found that data showed that a high percentage of black patients with rheumatoid arthritis had a cardiovascular disease factor and that about half had specific rheumatoid arthritis risk factors, such as joint erosions, elevated inflammatory markers, extra-articular disease, and body mass indexes below 20, which requires effective intervention.
Efficacy, Safety of Intravenous Golimumab Maintained Through 1 Year in Ankylosing Spondylitis
Researchers measured the safety and efficacy of intravenous golimumab in patients with active ankylosing spondylitis through 1 year.
New Clinical Rule May Help Physicians Identify Inflammatory Arthritis
Researchers created a model for general practitioners to use for patients who are atypical for detection of inflammatory arthritis, which included difficulty forming a fist, joint swelling (self-reported), between 1 and 3 painful joints, stiffness <1 hour in the morning, fewer than 6 weeks of symptom duration, male gender, and age of at least 60 years.
Denosumab Superior to Risedronate for Glucocorticoid-Induced Osteoporosis
Denosumab was superior to risedronate for increasing spine and hip BMD at 24 months of treatment.
Lesinurad Plus Xanthine Oxidase Inhibitor Therapy Linked to Increased Serum Creatinine Events
Rates of serum creatinine events were higher among patients treated with both lesinurad and a xanthine oxidase inhibitor.
